# CRABP-II siRNA (h): sc-35105



The Power to Question

#### **BACKGROUND**

The cellular retinoic acid-binding protein (CRABP)-I and a related isoform, CRABP-II, bind retinoic acid (RA), an important regulator of cell growth and differentiation in fetal and adult tissues. These CRABP proteins mediate the downstream effects of RA in distinct ways. CRABP-I negatively regulates the activity of RA by enhancing the production of RA-metabolizing enzymes and increasing the rate at which RA is degraded. CRABP-II enhances the effects of RA by directly interacting with RA receptors (RAR) and, in turn, promoting the formation of RAR-RA complexes and stimulating RA-mediated gene transcription. Both CRABP-I and CRABP-II are expressed in the embryo, and CRABP-I is ubiquitously expressed in various adult tissues. The expression of CRABP-II is elevated in cells that synthesize relatively large amounts of RA, and it is also predominantly expressed in skin, uterus, ovary and in the choroid plexus.

#### **REFERENCES**

- Wei, L.N., et al. 1990. Molecular cloning and transcriptional mapping of the mouse cellular retinoic acid-binding protein gene. DNA Cell Biol. 9: 471-478.
- Giguere, V., et al. 1990. Molecular cloning of cDNA encoding a second cellular retinoic acid-binding protein. Proc. Natl. Acad. Sci. USA 87: 6233-6237.
- Boylan, J.F. and Gudas, L.J. 1992. The level of CRABP-I expression influences the amounts and types of all-trans-retinoic acid metabolites in F9 teratocarcinoma stem cells. J. Biol. Chem. 267: 21486-21491.
- Gorry, P., et al. 1994. The cellular retinoic acid binding protein I is dispensable. Proc. Natl. Acad. Sci. USA 91: 9032-9036.

## **CHROMOSOMAL LOCATION**

Genetic locus: CRABP2 (human) mapping to 1g23.1.

#### **PRODUCT**

CRABP-II siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10  $\mu\text{M}$  solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see CRABP-II shRNA Plasmid (h): sc-35105-SH and CRABP-II shRNA (h) Lentiviral Particles: sc-35105-V as alternate gene silencing products.

For independent verification of CRABP-II (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-35105A, sc-35105B and sc-35105C.

### STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330  $\mu$ l of the RNAse-free water provided. Resuspension of the siRNA duplex in 330  $\mu$ l of RNAse-free water makes a 10  $\mu$ M solution in a 10  $\mu$ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

#### **APPLICATIONS**

CRABP-II siRNA (h) is recommended for the inhibition of CRABP-II expression in human cells.

#### **SUPPORT REAGENTS**

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

#### **GENE EXPRESSION MONITORING**

CRABP-I/II (F-9): sc-166897 is recommended as a control antibody for monitoring of CRABP-II gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG $\kappa$  BP-HRP: sc-516102 or m-lgG $\kappa$  BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker<sup>TM</sup> Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-lgG $\kappa$  BP-FITC: sc-516140 or m-lgG $\kappa$  BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz® Mounting Medium: sc-24941 or UltraCruz® Hard-set Mounting Medium: sc-359850.

#### **RT-PCR REAGENTS**

Semi-quantitative RT-PCR may be performed to monitor CRABP-II gene expression knockdown using RT-PCR Primer: CRABP-II (h)-PR: sc-35105-PR (20  $\mu$ l, 431 bp). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

#### **SELECT PRODUCT CITATIONS**

- 1. Gupta, A., et al. 2006. Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma. Cancer Res. 66: 8100-8108.
- Thulasiraman, P., et al. 2017. Activation of the CRABPII/RAR pathway by curcumin induces retinoic acid mediated apoptosis in retinoic acid resistant breast cancer cells. Oncol. Rep. 37: 2007-2015.
- 3. Xie, T., et al. 2022. CRABP2 accelerates epithelial mesenchymal transition in serous ovarian cancer cells by promoting TRIM16 methylation via upregulating EZH2 expression. Environ. Toxicol. 37: 1957-1967.
- 4. Liu, C.L., et al. 2022. CRABP2 is associated with thyroid cancer recurrence and promotes invasion via the integrin/FAK/AKT pathway. Endocrinology 163: bqac171.

#### **RESEARCH USE**

For research use only, not for use in diagnostic procedures.